drugset / Trial / NCT06254274

A Study of RAY1225 in Participants With Type 2 Diabetes

NCT06254274

Phase 2 Active not recruiting 210 enrolled Guangdong Raynovent Biotech Co., Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to learn more about the Tolerability of RAY1225 in participants with type 2 diabetes mellitus. The study will also explore the efficacy of RAY1225. The study will last about six months for each participant.

Timeline

Start
2024-02-26
Primary completion
2025-12-20
Completion
2025-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject RAY1225 Unknown Subcutaneous